WCLC 2025: Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with ES SCLC in IDeate-Lung01 Ph 2 Trial September 9, 2025
WCLC 2025: New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive NSCLC Announced September 9, 2025
Positive Topline Results for Sonrotoclax in R/R MCL Announced; primary endpoint of ORR met September 3, 2025
Initial Data Shows 100% Disease Control in all 5 Recurrent GBM patients and Near CR in 2, Treated With ANKTIVA® + Optune Gio® Device September 3, 2025
Ongoing Ph 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma showed 66% ORR and 50% CR in NHL patients September 3, 2025
Verzenio® (abemaciclib) increases OS in HR+, HER2-, high-risk early breast cancer with two years of therapy September 3, 2025
Nature Medicine Publishes Results of Ph 2 Study of Sacituzumab Tirumotecan Plus Tagitanlimab in 1L NSCLC August 26, 2025
Final Topline Survival Data from VERSATILE-002 Ph 2 Trial in 1L R/M HNSCC showing median OS of 39.3 months in patients with CPS ≥ 1 announced August 26, 2025
Early Data Demonstrates Tuspetinib Improves SOC Treatment Across Diverse Populations of Newly Diagnosed AML in Ph 1/2 TUSCANY Trial August 19, 2025
PADCEV Plus KEYTRUDA Significantly Improves Survival for Cisplatin-ineligible MIBC Patients When Given Before and After Surgery August 19, 2025
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit August 19, 2025
ELI-002 Updated AMPLIFY-201 Ph 1 Follow-up Data published in Nature Medicine for MRD Positive, Adjuvant-Stage Patients August 19, 2025
FAILED TRIAL: Clinical but not significant PFS Improvement seen in Ph 3 Trial of Cylembio® plus KEYTRUDA® in 1L Advanced Melanoma August 12, 2025
Ph 3 EPCORE® FL-1 Trial Met Dual Primary Endpoints in Patients with R/R Follicular Lymphoma August 12, 2025
Mid-year report of Ampligen® (rintatolimod) & Imfinzi® combo in pancreatic cancer demonstrates no significant toxicity and superior PFS and OS August 12, 2025
24-Month DOR of 72.2% Announced from Ph 3 ENVISION Trial of ZUSDURI in Recurrent Low-Grade Intermediate-Risk NMIBC August 12, 2025
Updated BEXMAB data in frontline HR-MDS shows complete remission rate substantially increased to 43% August 11, 2025
Positive Data Announced from Ph 2 CRDF-004 trial of onvansertib in 1L RAS-mutated mCRC August 5, 2025
Final Clinical Data Update from the NXP800 Ph 1b Study in Ovarian Cancer Provided and Completion of the NXP900 Ph 1a Dose Escalation Study Reported August 5, 2025
Jaypirca (pirtobrutinib) met primary endpoint in a head-to-head Ph 3 trial versus Imbruvica (ibrutinib) in CLL/SLL August 5, 2025
Preliminary Safety & Efficacy Data Announced from Trial of IMM2510/AXN-2510 in Combination with Chemo in 1L NSCLC in China August 5, 2025
Clinically Meaningful Improvement in Both PFS Primary Endpoints from PIK3CA WT Cohort of Ph 3 VIKTORIA-1 Trial Announced July 29, 2025
Positive Data from Long-Term Follow-Up Analysis of the Ph 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated AML Announced July 29, 2025
